Biopharma 2022: The Resilience Rethink

Cytiva’s Global Biopharma Resilience Index is the first of its kind to put a number on the strength of, and confidence in, the biopharma industry. 1000 senior pharma executives and healthcare policymakers across 20 countries were asked about five areas: supply chain resilience, access to talent, strength of the R&D ecosystem, manufacturing agility, and the extent to which government policy and regulation supports the industry in helping to serve more patients worldwide. The Index gives us a deep and comprehensive view, country by country, of how biopharma is doing. Download the full report to explore the findings in detail.